GLP-1 Innovation team_NSM 2018
1. What is the Incentive amount you are eligible at 100% sales achievement p.a (Both Sales & Activity)?
200000
250000
700000
None of the above
4. What is the maximum incentive you can earn per annum (Both Sales & Activity)?
250000
600000
700000
None of the Above
6. In NN, we follow any applicable laws, regulations and industry codes. We also follow our own business ethics standards and procedures (Novo Nordisk Code of ConducAccording to the Business Ethics Code of Conduct, which of the following statements is correct?
Local law and industry code may be disregarded, if my local legal department approves it
Novo Nordisk standards and procedures may be overruled if more stringent rules apply locally
Either of above
7. An employee invites an HCP as a speaker for a meeting to be held on 20th August 2017. You send the request for contract preparation to the legal department by filling up the contract initiation template. Amount to be paid for the services is INR 50,000. When you will calculate FMV?
At the time of payment
At the time of preparation of the contract
Either of the above
None of the above
8. In a Sponsorship, the following is acceptable:
Payment routed to HCP’s directly need not include any follow up documentation.
While Sponsoring an event, commercial benefit for Novo Nordisk and disclosure of the fact that the event has been sponsored by Novo Nordisk is not required if sponsorship amount is below INR 5,00,000.00.
Follow up on fund utilisation is not required if sponsorship amount is below INR 5,00,000.00.
The commercial benefit to Novo Nordisk, disclosure of the fact that the event has been sponsored by Novo Nordisk, agreement and proper follow-up documentation from the institution.
9. Ryzodeg meeting took place on 1st July 2017. Timings as per agenda was 8:00 to 10:00 PM, with dinner scheduled from 9:30 to 10:00 PM. Due to unavoidable circumstances, meeting started at 8:30 PM. Meeting ended at 10:45 pm. But hotel invoice was generated at 12:00 pm. How will you abide by 75/25 rule for the scientific meeting?
I will inform Manager and pay the hotel as per his instructions
I will pay the hotel and thereafter raise exception for deviation from 25/75 rule and document the reason for delay in the start of the meeting
There is no deviation as such in the situation as it occurred due to unavoidable circumstances
None of the above
10. An employee invites a doctor (HCP) as a speaker for a meeting. The HCP accepts the invitation. He is accompanied to the meeting by his friend, who is also a doctor and practices in the field of endocrinology.
It can be accommodated as the friend is also a doctor.
Though the friend is a doctor, he has not been invited to the event by Novo Nordisk. Therefore, you should politely let the HCP know that it is not accepted as per internal policies.
Though the friend is a doctor, he has not been invited to the event by Novo Nordisk. Therefore, you should politely let the HCP know that it is not accepted as per internal policies. If the friend still attends the event, you should document it
11. Which of the following factors are considered for career progression from a Product Specialist to a Sr product specialist?
3P Rating
Minimum years of experience
Recommendation form Line manager
All of the above
12. Which of the following options regarding Goal Setting is completely TRUE for 2018 process:
Your Goal plan will remain open until Goal plan sign- off and it is recommended to have maximum 5 goals with minimum 10% weight;
Your Goal plan will remain open until Goal plan sign- off and it is recommended to have maximum 10 goals with minimum 5% weight;
Your Goal plan will remain open until mid-year sign- off and it is recommended to have maximum 10 goals with minimum 5% weight;
Your Goal plan will remain open until mid-year sign- off and it is recommended to have maximum 12 goals with minimum 5% weight;
13. Which of the following statements is FALSE for 2018 performance management process:
Your performance rating will impact your annual salary increase
Your performance rating will not impact your selection to development programmes
Your 3P rating will serve as an input for career progression
Your performance rating will be solely decided by your manager’s discretion.
15. Which of the following statements is true for 2018 Talent Development Program Nomination
Your performance rating will be considered for your nomination
Your performance rating along with manager’ inputs will be considered for your nomination
Your cumulative health score card will be considered for your nomination
Your sales performance will be considered for your nomination
16. All employees should report any customer complaint (Product defect/AE/SAE) or safety information to
Safety Team (INAGREE@novonordisk.com)
GM (General Manager)
HQ (Head Quarters)
None of the above
17. Which of the below need to be reported
Use of NN product in pregnancy
Any technical complaint
Any adverse Event
All the above
18. If an HCP requests for off label information you should contact
GM
Medical Department
Finance Department
Do not know
19. In case if you observe errors in label, promotional material contact
Line Manager & QA
No need to report to any one
Distribute to HCP with error
Do not know
20. Corrections to printed or handwritten data must be made so that the original text is:
Strikethrough so nothing is readable
Strikethrough but readable
Completely covered using a whitener
Enter duplicate data
21. Which are the key components of MACE?
Cardiovascular death & Non-fatal Myocardial Infarction
Cardiovascular death, Non-fatal Myocardial Infarction & Heart Failure
Cardiovascular death, Non-fatal Myocardial Infarction & Non- Fatal Stroke
Hospitalisation for acute coronary syndrome, Urgent revascularisation procedures & Heart failure
22. What is expanded 4-point MACE?
Hospitalisation for acute coronary syndrome, Urgent revascularisation procedures & Heart failure
Cardiovascular death, Non-fatal Myocardial Infarction & Heart Failure & fatal Myocardial Infarction
Cardiovascular death, Non-fatal Myocardial Infarction, Non- Fatal Stroke & hospitalisation for unstable angina or heart failure
Cardiovascular death, Non-fatal Stroke, Heart Failure & fatal Myocardial Infarction
23. To prove the drug to be superior the upper limit of the 95% CI of the hazard ratio should be:
1.3-1.8
>1.8
<1
1-1.3
25. If the Hazard ratio of CV outcome study comparing Drug A with Placebo is 1.87. It means:
Drug A has more CV risk
Placebo has less CV risk
Drug A has less CV risk
Both Drug A & Placebo increase the CV risk
26. Primary endpoint (MACE events) showed …………… risk reduction in liraglutide group vis a vis placebo group
15%
14%
13%
12%
27. In LEADER trial the hazard ratio for CV death in liraglutide arm :
Decreased By 22% But Was Non-Significant
Increased By 26% But Was Non-Significant
Decreased By 22% But Was Significant
Increased By 15% But Was Significant
29. Effects of GLP-1 on the cardiovascular system are:
Improves cardiac function in heart failure
Increases myocardial glucose uptake
Mproves functional recovery following myocardial ischaemia
Reduces infarct size & improves endothelium dysfunction
All of the above
30. The reduction in CV events with liraglutide appeared independent of:
Baseline insulin or CV medication use
Initiation of insulin or SU/TZD during the trial
Experiencing an episode of severe hypoglycemia
All of the above
31. Regarding Dulaglutide and liraglutide which one is false:
The molecular size of Dulaglutide is 59 kD and liraglutide is 3.9 kD
The needle gauge in dulaglutide pen in 29 G and liraglutide is 31 G
Dulaglutide achieved non inferiority over liraglutide on weight parameters in AWARD 6
Both dulaglutide and liraglutide are human based GLP-1 analogues
33. In AWARD -6 the reduction in HbA1c (%) with liraglutide and dulaglutide is :
1.42 and 1.33
1.36 and 1.42
1.05 and 1.50
1.8 and 1.3
34. In AWARD -6 the reduction in weight (kg) with liraglutide and dulaglutide is :
3.61 and 2.90
2.90 and 3.61
1.05 and 1.50
1.8 and 1.3
35. In AWARD -6 the patient compliance with liraglutide and dulaglutide is :
85.3 and 90.2
95.2 and 99.2
97.5 and 98.2
94.3 and 95.4
36. The CVOT for liraglutide and dulaglutide is dulaglutide is :
ELIXA and SAVOR TIMI
LEADER and REWIND
LEADER and EXCEL
TECOS and LEADER
37. The percentage of patients achieving HbA1c target of <7 m% with liraglutide and dulaglutide is AWARD -6 is :
70.2 and 68.4
67.9 and 68.3
65.7 and 69.2
72.2 and 71.3
38. Which of the following is true regarding the design of AWARD -6 :
4 week lead in period followed by 26 weeks treatment period and 4 week safety follow up
2 week lead in period followed by 26 weeks treatment period and 4 week safety followup
2 week lead in period followed by 56 weeks treatment period and 4 week safety followup
D) 4 week lead in period followed by 56 weeks treatment period and 2 week safety followup
39. Select the most probable reason for less weight loss with dulaglutide in comparison to liraglutide in AWARD -6 in spite :
Larger size of the molecule makes dulaglutide less available in the blood circulation
Larger size of dulaglutide makes entry into the CNS difficult
Lower effect on the gastric emptying with dulaglutide
More nausea with liraglutide causes more weight loss
40. Select the wrong option from the below ones regarding AWARD -6 in spite :
PRIMARY OBJECTIVE : Non-inferiority of dulaglutide 1.5 mg to liraglutide 1.8 mg on
KEY SECONDARY OBJECTIVE : Superiority of dulaglutide 1.5 mg to liraglutide 1.8 mg on HbA1c change from baseline to Week 26
One of the Key exclusion criteria was Elevated calcitonin (≥20 pg/ml)
One of the Key inclusion criteria was HbA1c ≥8.0% and ≤11.0%
42. Primary Endpoint of LEADER trial was the occurrence of:
Death from any cause or Death from MI or death from stroke
Death from MI or non-fatal MI or non-fatal stroke
Death from cardiovascular causes or non-fatal MI or non-fatal stroke
Any death from any cause
43. In LEADER trial patients were randomized to
Liraglutide : Glargine
Liraglutide : Placebo
Liraglutide : Exenatide
Liraglutide : Semaglutide
45. LEADER trial included ……………. Patients who were at high risk for cardiovascular disease
Type 1 diabetes
Type 2 diabetes
Both
None
{"name":"GLP-1 Innovation team_NSM 2018", "url":"https://www.quiz-maker.com/QPREVIEW","txt":"How many levers are there in Sales effectiveness, How many levers are there in marketing effectivness, Quality of Interaction is lever no.?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}